{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:23Z","timestamp":1791999263623,"version":"4.4.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>The landscape of cancer survival has been positively affected by the introduction and dissemination of immunotherapy with the wide usage of immune checkpoint inhibitors and chimeric antigen receptors cell therapies. The success of these novel therapies can, however, be limited to a certain extent by systemic inflammatory toxicities affecting, directly or indirectly, the kidney. In the case of immune checkpoint inhibitors, severe acute interstitial nephritis is the main adverse event and can lead to permanent discontinuation of the therapy. In turn, chimeric antigen receptor cell therapy can cause cytokine release syndrome and immune effector cell-associated hemophagocytic lympho-histiocytosis, with kidney damage through various mechanisms, and be life threatening. Prompt diagnosis and management of these entities is essential to preserve kidney function and ensure the best possible kidney and overall outcomes to patients with cancer.<\/jats:p>","DOI":"10.34067\/kid.0000000749","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:00:55Z","timestamp":1740398455000},"page":"652-662","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Acute Kidney Injury Associated with Novel Anticancer Therapies"],"prefix":"10.34067","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-0241","authenticated-orcid":false,"given":"Sabine","family":"Karam","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Minneapolis"},{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5538-6068","authenticated-orcid":false,"given":"Ala","family":"Ali","sequence":"additional","affiliation":[{"name":"Nephrology and Renal Transplantation Center, The Medical City, Baghdad, Iraq"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-7628","authenticated-orcid":false,"given":"Winston","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8151-4331","authenticated-orcid":false,"given":"Prashant","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Oncology and Bone Marrow Transplantation, Amrita Institute of Medical Sciences and Research Centre, Faridabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7469-2789","authenticated-orcid":false,"given":"Sanjeev","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Madras Medical Mission, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3298-8642","authenticated-orcid":false,"given":"Urmila","family":"Anandh","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Amrita Institute of Medical Sciences and Research Centre, Faridabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"issue":"262","key":"B1-20250609","first-page":"3","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas","author":"Coley","year":"1991","journal-title":"Clin Orthop Relat Res."},{"key":"B2-20250609","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen","volume":"2012","author":"Brentjens","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"4","key":"B3-20250609","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med."},{"issue":"16","key":"B4-20250609","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med."},{"issue":"22","key":"B5-20250609","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1182\/bloodadvances.2020002537","article-title":"Fundamentals of immunology for understanding immunotherapy for lymphoma","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv."},{"key":"B6-20250609","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/bs.acr.2024.05.004","article-title":"Recent advances and progress in immunotherapy of solid cancers","volume":"164","author":"Kumar","year":"2024","journal-title":"Adv Cancer Res."},{"issue":"10","key":"B7-20250609","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol."},{"issue":"1","key":"B8-20250609","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/ijms25010414","article-title":"Nephrotoxicity in the age of immune checkpoint inhibitors: mechanisms, diagnosis, and management","volume":"25","author":"Moturi","year":"2023","journal-title":"Int J Mol Sci."},{"issue":"5","key":"B9-20250609","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ackd.2021.07.006","article-title":"Immunotherapy-related acute kidney injury","volume":"28","author":"Manohar","year":"2021","journal-title":"Adv Chronic Kidney Dis."},{"issue":"5","key":"B10-20250609","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol."},{"issue":"2","key":"B11-20250609","doi-asserted-by":"crossref","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open."},{"key":"B12-20250609","doi-asserted-by":"crossref","first-page":"118110","DOI":"10.1016\/j.lfs.2020.118110","article-title":"Immune escape: a critical hallmark in solid tumors","volume":"258","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"issue":"12","key":"B13-20250609","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","journal-title":"Nat Rev Nephrol."},{"key":"B14-20250609","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol."},{"issue":"6029","key":"B15-20250609","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science."},{"issue":"8","key":"B16-20250609","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood."},{"issue":"6","key":"B17-20250609","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med."},{"issue":"6","key":"B18-20250609","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med."},{"issue":"2","key":"B19-20250609","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"B20-20250609","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer."},{"key":"B21-20250609","doi-asserted-by":"crossref","first-page":"1353339","DOI":"10.3389\/fimmu.2024.1353339","article-title":"Immune checkpoint inhibitors and acute kidney injury","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol."},{"issue":"1","key":"B22-20250609","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"issue":"1","key":"B23-20250609","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","article-title":"A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B24-20250609","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant."},{"key":"B25-20250609","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","article-title":"Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence","volume":"115","author":"Xie","year":"2023","journal-title":"Eur J Intern Med."},{"key":"B26-20250609","doi-asserted-by":"crossref","first-page":"1173952","DOI":"10.3389\/fimmu.2023.1173952","article-title":"Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol."},{"issue":"1","key":"B27-20250609","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12882-023-03171-9","article-title":"Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database","volume":"24","author":"Chen","year":"2023","journal-title":"BMC Nephrol."},{"issue":"12","key":"B28-20250609","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B29-20250609","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cac2.12396","article-title":"Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun."},{"issue":"5","key":"B30-20250609","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MNH.0000000000000805","article-title":"Immune checkpoint inhibitors and kidney disease","volume":"31","author":"Wang","year":"2022","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"15 suppl","key":"B31-20250609","doi-asserted-by":"crossref","first-page":"e15160","DOI":"10.1200\/JCO.2020.38.15_suppl.e15160","article-title":"Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors","volume":"38","author":"Qin","year":"2020","journal-title":"J Clin Oncol."},{"issue":"7","key":"B32-20250609","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"B33-20250609","doi-asserted-by":"crossref","first-page":"1043874","DOI":"10.3389\/fneph.2023.1043874","article-title":"The need for kidney biopsy in the management of side effects of target and immunotherapy","volume":"3","author":"Fenoglio","year":"2023","journal-title":"Front Nephrol."},{"issue":"36","key":"B35-20250609","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol."},{"issue":"8","key":"B36-20250609","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B37-20250609","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int."},{"issue":"1","key":"B38-20250609","doi-asserted-by":"crossref","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","journal-title":"Oncoimmunology."},{"issue":"10","key":"B39-20250609","doi-asserted-by":"crossref","first-page":"e127456","DOI":"10.1172\/jci.insight.127456","article-title":"Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis","volume":"4","author":"Moledina","year":"2019","journal-title":"JCI Insight."},{"issue":"13","key":"B40-20250609","doi-asserted-by":"crossref","first-page":"e168950","DOI":"10.1172\/JCI168950","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"133","author":"Moledina","year":"2023","journal-title":"J Clin Invest."},{"issue":"1","key":"B41-20250609","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","article-title":"Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis","volume":"7","author":"Qualls","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"3","key":"B42-20250609","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00330-022-09158-8","article-title":"Imaging features of immune checkpoint inhibitor-related nephritis with clinical correlation: a retrospective series of biopsy-proven cases","volume":"33","author":"Awiwi","year":"2023","journal-title":"Eur Radiol."},{"issue":"4","key":"B43-20250609","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"3","key":"B44-20250609","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B45-20250609","doi-asserted-by":"crossref","first-page":"e006222","DOI":"10.1136\/jitc-2022-006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","journal-title":"J Immunother Cancer."},{"issue":"1","key":"B46-20250609","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12967-024-05177-9","article-title":"Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression","volume":"22","author":"Martinez Valenzuela","year":"2024","journal-title":"J Transl Med."},{"issue":"18","key":"B47-20250609","doi-asserted-by":"crossref","first-page":"e182275","DOI":"10.1172\/JCI182275","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor\u2013associated acute kidney injury","volume":"134","author":"Gupta","year":"2024","journal-title":"J Clin Invest."},{"issue":"5","key":"B48-20250609","first-page":"887","article-title":"Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors","volume":"37","author":"Garc\u00eda-Carro","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B49-20250609","doi-asserted-by":"crossref","first-page":"e0252978","DOI":"10.1371\/journal.pone.0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","journal-title":"PLoS One."},{"issue":"5","key":"B50-20250609","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clin Exp Nephrol."},{"key":"B51-20250609","doi-asserted-by":"crossref","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol."},{"key":"B52-20250609","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine."},{"issue":"1","key":"B53-20250609","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","article-title":"CAR-T cell potency: from structural elements to vector backbone components","volume":"10","author":"Mazinani","year":"2022","journal-title":"Biomark Res."},{"issue":"6","key":"B54-20250609","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B55-20250609","doi-asserted-by":"crossref","first-page":"797440","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front Bioeng Biotechnol."},{"key":"B56-20250609","doi-asserted-by":"crossref","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"B57-20250609","doi-asserted-by":"crossref","first-page":"e003351","DOI":"10.1136\/jitc-2021-003351","article-title":"Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants","volume":"9","author":"Conde","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"1","key":"B58-20250609","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B59-20250609","doi-asserted-by":"crossref","first-page":"100362","DOI":"10.1016\/j.cotox.2022.100362","article-title":"Immunotherapies and renal injury","volume":"31","author":"Shaikh","year":"2022","journal-title":"Curr Opin Toxicol."},{"issue":"6","key":"B60-20250609","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"B61-20250609","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy Tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B62-20250609","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/ndt\/gfac048","article-title":"Renal outcomes after chimeric antigen receptor T-cell therapy: a single-center perspective","volume":"37","author":"Ansari","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"B63-20250609","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B64-20250609","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood."},{"issue":"5","key":"B65-20250609","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B66-20250609","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-cell therapy","volume":"12","author":"Penack","year":"2020","journal-title":"Cancers."},{"issue":"8","key":"B67-20250609","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"B68-20250609","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"suppl 1","key":"B69-20250609","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): real world experience from the center for international blood & marrow transplant research (CIBMTR) cellular therapy (CT) registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood."},{"key":"B70-20250609","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.omto.2019.08.002","article-title":"Parallel comparison of 4-1BB or CD28 Co-stimulated CD19-targeted CAR-T cells for B cell non-hodgkin\u2019s lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther Oncolytics."},{"issue":"21","key":"B71-20250609","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers."},{"issue":"8","key":"B72-20250609","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med."},{"issue":"2-3","key":"B73-20250609","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s44228-023-00037-7","article-title":"Safety of CAR-T cell therapy in patients with renal failure\/acute kidney injury: focused review","volume":"5","author":"Khan","year":"2023","journal-title":"Clin Hematol Int."},{"issue":"6","key":"B74-20250609","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17474086.2016.1183479","article-title":"Medical management of side effects related to CAR T cell therapy in hematologic malignancies","volume":"9","author":"Namuduri","year":"2016","journal-title":"Expert Rev Hematol."},{"issue":"2","key":"B75-20250609","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere."},{"issue":"6","key":"B76-20250609","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"B77-20250609","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov."},{"issue":"4","key":"B78-20250609","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv."},{"issue":"10","key":"B79-20250609","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica."},{"key":"B80-20250609","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J Crit Care."},{"issue":"6","key":"B81-20250609","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med."},{"issue":"1","key":"B82-20250609","doi-asserted-by":"crossref","first-page":"2326186","DOI":"10.1080\/0886022X.2024.2326186","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study","volume":"46","author":"Zhou","year":"2024","journal-title":"Ren Fail."},{"issue":"10","key":"B83-20250609","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"1","key":"B84-20250609","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med."},{"key":"B85-20250609","doi-asserted-by":"crossref","first-page":"1125357","DOI":"10.3389\/fimmu.2023.1125357","article-title":"Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol."},{"issue":"6","key":"B86-20250609","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell (CAR-T) therapy: a case report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med."},{"issue":"1","key":"B87-20250609","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CNCS111045","article-title":"Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy","volume":"11","author":"Wu","year":"2023","journal-title":"Clin Nephrol Case Stud."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:03:00Z","timestamp":1786478580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000749"}},"subtitle":["Immunotherapy"],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000749","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}